Genus Past Earnings Performance
Past criteria checks 2/6
Genus has been growing earnings at an average annual rate of 15.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 7.4% per year. Genus's return on equity is 5.3%, and it has net margins of 5%.
Key information
15.3%
Earnings growth rate
15.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 7.4% |
| Return on equity | 5.3% |
| Net Margin | 5.0% |
| Next Earnings Update | 05 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Genus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 673 | 33 | 101 | 93 |
| 30 Sep 23 | 681 | 33 | 100 | 93 |
| 30 Jun 23 | 690 | 33 | 99 | 93 |
| 31 Mar 23 | 676 | 34 | 94 | 83 |
| 31 Dec 22 | 662 | 34 | 90 | 73 |
| 30 Sep 22 | 628 | 38 | 89 | 73 |
| 30 Jun 22 | 593 | 41 | 89 | 73 |
| 31 Mar 22 | 582 | 39 | 92 | 71 |
| 31 Dec 21 | 570 | 37 | 95 | 68 |
| 30 Sep 21 | 572 | 42 | 96 | 68 |
| 30 Jun 21 | 574 | 47 | 97 | 68 |
| 31 Mar 21 | 570 | 45 | 93 | 70 |
| 31 Dec 20 | 566 | 42 | 89 | 71 |
| 30 Sep 20 | 559 | 39 | 89 | 71 |
| 30 Jun 20 | 551 | 35 | 88 | 71 |
| 31 Mar 20 | 536 | 37 | 80 | 66 |
| 31 Dec 19 | 520 | 39 | 72 | 61 |
| 30 Sep 19 | 504 | 23 | 72 | 61 |
| 30 Jun 19 | 489 | 8 | 72 | 61 |
| 31 Mar 19 | 480 | 1 | 76 | 56 |
| 31 Dec 18 | 471 | -7 | 81 | 51 |
| 30 Sep 18 | 470 | 18 | 81 | 51 |
| 30 Jun 18 | 470 | 43 | 82 | 51 |
| 31 Mar 18 | 473 | 55 | 80 | 48 |
| 31 Dec 17 | 476 | 67 | 79 | 45 |
| 30 Sep 17 | 467 | 50 | 79 | 45 |
| 30 Jun 17 | 459 | 33 | 78 | 45 |
| 31 Mar 17 | 441 | 40 | 75 | 40 |
| 31 Dec 16 | 422 | 47 | 71 | 34 |
| 30 Sep 16 | 405 | 48 | 71 | 34 |
| 30 Jun 16 | 388 | 49 | 71 | 34 |
| 31 Mar 16 | 388 | 40 | 68 | 32 |
| 31 Dec 15 | 388 | 31 | 64 | 29 |
| 30 Sep 15 | 393 | 35 | 64 | 29 |
| 30 Jun 15 | 399 | 40 | 64 | 29 |
| 31 Mar 15 | 394 | 36 | 60 | 28 |
| 31 Dec 14 | 389 | 32 | 56 | 28 |
| 30 Sep 14 | 381 | 30 | 57 | 28 |
| 30 Jun 14 | 372 | 29 | 58 | 28 |
| 31 Mar 14 | 366 | 27 | 59 | 28 |
| 31 Dec 13 | 360 | 25 | 60 | 28 |
| 30 Sep 13 | 353 | 24 | 60 | 28 |
| 30 Jun 13 | 345 | 23 | 60 | 28 |
Quality Earnings: GENS.F has high quality earnings.
Growing Profit Margin: GENS.F's current net profit margins (5%) are lower than last year (5.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GENS.F has become profitable over the past 5 years, growing earnings by 15.3% per year.
Accelerating Growth: GENS.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GENS.F had negative earnings growth (-2.9%) over the past year, making it difficult to compare to the Biotechs industry average (-8.9%).
Return on Equity
High ROE: GENS.F's Return on Equity (5.3%) is considered low.